Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-week, Randomized, Double-blind, Parallel-group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose

NCT00819767 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00819767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00819767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-week, Randomized, Double-blind, Parallel-group, Pilot Study to Evaluate the Efficacy and Safety of Aliskiren 300 mg in Comparison With Valsartan 320 mg in Patients With Mild to Moderate Hypertension During Exercise After a Missed Dose
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
October 31, 2009
Enrollment
68 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension